Skip to main content
TEYI PHARMACEUTICAL GROUP CO.,LTD logo

TEYI PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002728 ISIN · CNE100001WK6 LEI · 300300ZUIZCFPGQWOZ61 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,596 across all filing types
Latest filing 2024-12-02 Share Issue/Capital Cha…
Country CN China
Listing Shenzhen Stock Exchange 002728

About TEYI PHARMACEUTICAL GROUP CO.,LTD

https://www.tczy.com.cn

TEYI PHARMACEUTICAL GROUP CO.,LTD. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio primarily consists of Chinese patent medicines and chemical drug preparations. Its flagship product, Zhike Bao Tablets, is widely recognized for treating chronic bronchitis and cough-related ailments. Beyond respiratory health, the group produces a diverse range of medications covering cardiovascular diseases, gastrointestinal disorders, and anti-infective treatments. Teyi Pharmaceutical operates modern production facilities and maintains a robust distribution network to serve healthcare providers and pharmacies. The company emphasizes the integration of traditional medicinal knowledge with modern pharmaceutical technology to enhance product efficacy and safety.

Recent filings

Filing Released Lang Actions
章程修正案
Share Issue/Capital Change Classification · 95% confidence The document is a formal announcement regarding amendments to the company's articles of association (公司章程) due to changes in registered capital and share capital. It details specific changes in capital figures and states that the amendments will be submitted to the shareholders' meeting and regulatory authorities for approval and registration. The document is short (619 characters) and primarily concerns governance and capital structure changes, not a full report or financial statement. It is not a full Annual Report, Interim Report, or Audit Report. It is not a simple announcement of a report publication but a substantive governance-related announcement. The best fitting category is Share Issue/Capital Change (SHA) because it involves changes in registered capital and share capital reflected in the articles of association.
2024-12-02 Chinese
关于第五届董事会第二十六次会议决议的公告
Board/Management Information Classification · 95% confidence The document is an announcement of resolutions passed at a board of directors meeting of 特一药业集团股份有限公司. It details the meeting date, attendance, and specific decisions made, such as stock option cancellations, stock option exercise conditions, appointment of an audit firm, changes in registered capital and company bylaws, changes in use of raised funds, and scheduling of a shareholders meeting. The document is a formal announcement of board decisions rather than a full report or financial statement. It does not contain financial data or detailed financial analysis. The content fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors. The document length is 2578 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the appropriate classification is MANG with high confidence.
2024-12-02 Chinese
关于独立董事连续任职满六年辞职的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the resignation of two independent directors who have served the maximum term of six years. It discusses compliance with regulatory rules about director tenure and the process for their replacement. There is no financial data, no mention of financial results, no report attached or referenced, and no discussion of management changes beyond the resignation of directors. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2024-11-26 Chinese
关于提前归还可转债部分暂时补充流动资金的募集资金的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company regarding the early repayment of part of the funds temporarily used from convertible bond proceeds to supplement working capital. It details the board meeting decision, amounts involved, repayment status, and references a previous announcement. The document is short (912 characters) and focuses on a specific financing activity related to convertible bonds and the use of raised funds. It does not contain financial statements or comprehensive financial data, nor is it a full report. This fits the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2024-11-19 Chinese
关于股份回购进展情况的公告
Transaction in Own Shares Classification · 100% confidence The document is a formal announcement from 特一药业集团股份有限公司 regarding the progress of its share repurchase program. It details the number of shares repurchased, the price range, total funds used, and compliance with relevant regulations. The text explicitly mentions the repurchase of company shares, the source of funds, and adherence to regulatory rules. The document length is relatively short (1426 characters) and focuses solely on the update of the share buyback activity, not on broader financial results or other corporate matters. This matches the definition of a 'Transaction in Own Shares' filing, which reports on the company's buyback or sale of its own shares. Therefore, the correct classification is POS (Transaction in Own Shares).
2024-11-01 Chinese
2024年三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2024 Third Quarter Report" of 特一药业集团股份有限公司, indicating it is a quarterly financial report. It contains detailed financial statements including balance sheets, profit and loss statements, and cash flow statements for the third quarter of 2024. The document explicitly states it is a quarterly report and is unaudited. The length of the document (over 13,000 characters) and the presence of comprehensive financial data confirm it is a substantive financial report rather than a brief announcement or certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q3 2024
2024-10-25 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.